Home / Market News / $ALC
benzinga Corporate Catalyst Impact 92/100 ● neutral

Alcon Acquires Neurotech Pharmaceuticals For $550M

Oct 20, 2026, 8:36 PM UTC · Primary ticker $ALC

Alcon has acquired Neurotech Pharmaceuticals for $550 million, gaining ENCELTO, an FDA-approved treatment for Macular Telangiectasia Type 2. This strategic acquisition significantly expands Alcon's retina portfolio and introduces a new, approved therapy for a previously untreatable rare eye disease, potentially boosting future revenue streams.

Alcon has acquired Neurotech Pharmaceuticals for $550 million, with potential for additional contingent payments. This acquisition is significant because it brings ENCELTO, the first and only U.S. FDA-approved treatment for idiopathic Macular Telangiectasia Type 2 (MacTel), into Alcon's retina portfolio. This is a major positive for Alcon as it diversifies its product offerings and enters a new, high-value market segment for a rare disease with no prior approved treatments. The short-term implication is increased R&D and integration costs, but the long-term opportunity is substantial revenue growth from a novel, approved therapy. Traders should note the potential for future contingent payments, which could impact Alcon's financials depending on ENCELTO's commercial success.

$ALC positive Acquires new FDA-approved therapy, expands portfolio
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.